ArticleCell reports. Medicine2022
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03226886 (TRACERx Renal), which is not on this map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TRACERx Renal (TRAcking Renal Cell Carcinoma Evolution Through Therapy (Rx)) CAPTURE: COVID-19 Antiviral Response in a Pan-tumour Immune Study
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows.Cell reports methods · 2026Article
- Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review.The oncologist · 2025Review
- The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review.Preventive medicine reports · 2024Review
- Oral antivirals for COVID-19 among patients with cancer.Research square · 2024Article
- Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2.RSC advances · 2023Review
- Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19.Clinical and experimental medicine · 2023Article
- Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.British journal of haematology · 2023Article
- COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.The Journal of infectious diseases · 2023Review
- Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states.Science translational medicine · 2023Article
- Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.Cancer cell · 2023Article
- mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.International journal of molecular sciences · 2023Review
- SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants.Pathogens (Basel, Switzerland) · 2023Review
- Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19.Research square · 2023Article
- Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.Frontiers in immunology · 2023Article
- Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors at 4 institutions in 2 countries.
Annika FendlerCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Scott T C ShepherdCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Lewis AuCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Mary WuCOVID Surveillance Unit, The Francis Crick Institute, London NW1 1AT, UK.
Ruth HarveyWorldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.
Katalin A WilkinsonTuberculosis Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory 7925, Republic of South Africa.
Andreas M SchmittSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Zayd TippuCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Benjamin ShumCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Sheima FaragSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Aljosja RogiersSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Eleanor CarlyleSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Kim EdmondsSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Lyra Del RosarioSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Karla LingardSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Mary MangwendeSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Lucy HoltSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Hamid AhmodSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Justine KortewegSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Tara FoleySkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Taja BarberCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Andrea Emslie-HenryCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Niamh Caulfield-LynchCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Fiona ByrneCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Daqi DengCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Svend KjaerStructural Biology Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
Ok-Ryul SongHigh Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Christophe J QuevalHigh Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Caitlin KavanaghCOVID Surveillance Unit, The Francis Crick Institute, London NW1 1AT, UK.
Emma C WallHigh Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London WC1E 6BT, UK.
Edward J CarrCell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Simon CaidanSafety, Health & Sustainability, The Francis Crick Institute, London NW1 1AT, UK.
Mike GavrielidesScientific Computing Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
James I MacRaeMetabolomics Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
Gavin KellyDepartment of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
Kema PeatSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Denise KellySkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Aida MurraSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Kayleigh KellySkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Molly O'FlahertySkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Robyn L SheaDepartment of Pathology, The Royal Marsden NHS Foundation Trust, London NW1 1AT, UK; Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London SW7 3RP, UK.
Gail GardnerDepartment of Pathology, The Royal Marsden NHS Foundation Trust, London NW1 1AT, UK.
Darren MurrayDepartment of Pathology, The Royal Marsden NHS Foundation Trust, London NW1 1AT, UK.
Sanjay PopatLung Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Nadia YousafLung Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Shaman JhanjiAnaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Kate TathamAnaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
David CunninghamGastrointestinal Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK.
Nicholas Van AsClincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London NW1 1AT, UK.
Kate YoungSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Andrew J S FurnessSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Lisa PickeringSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Rupert BealeCell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Division of Medicine, University College London, London NW1 2PG, UK.
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK; University College London Cancer Institute, London WC1E 6DD, UK.
Sonia GandhiNeurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
Steve GamblinStructural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
David L V BauerRNA Virus Replication Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
George KassiotisRetroviral Immunology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Michael HowellHigh Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Emma NicholsonHaemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Haemato-oncology Unit, The Institute of Cancer Research, London SW7 3RP, UK.
Susanna WalkerAnaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Robert J WilkinsonTuberculosis Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Wellcome Center for Infectious Disease Research in Africa, University of Cape Town, Observatory 7925, Republic of South Africa; Department of Infectious Disease, Imperial College London, London W2 0NN, UK.
James LarkinSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK.
Samra TurajlicCancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: samra.turajlic@crick.ac.uk.
Royal Marsden NHS Foundation Trust · GBThe Francis Crick Institute · GBUniversity of Cape Town · ZAUniversity College London Hospitals NHS Foundation Trust · GB
Funding
Cancer Research UK 18176Cancer Research UK 29911Cancer Research UK C50947/A18176Department of HealthMedical Research Council MR/W005611/1Wellcome Trust FC001002Wellcome Trust FC001030Wellcome Trust FC001078Wellcome Trust FC001099Wellcome Trust FC001169Wellcome Trust FC001218Wellcome Trust FC001988Wellcome Trust FC011104
Abstract
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
Indexed as
COVID-19COVID-19 VaccinesNeoplasmsAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineClinical Studies as TopicHumansImmunitySARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 Vaccinesblood cancerCOVID-19neutralizing antibodiesSARS-CoV-2T cellsvariants of concern
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03226886ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.